This activity is intended for pulmonologists, infectious disease clinicians, internists, family medicine and primary care clinicians, pharmacists, nurses, and other members of the healthcare team for patients with COVID-19.
The goal of this activity is that learners will be better able to describe chest computed tomography (CT) findings and functional small airways disease (fSAD) in patients with post-acute sequelae of COVID-19 (PASC), according to a single-center study at a university teaching hospital.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-105-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of
continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the
valid credit period that
is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in
your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as
the certificates from the
CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 4/29/2022
Valid for credit through: 4/29/2023, 11:59 PM EST
processing....
Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to COVID-19 vaccines may be provided in this activity to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.
Nearly 30% of patients with post-acute sequelae of COVID-19 (PASC), including persons who had mild infection not requiring hospitalization, have persistent respiratory symptoms. Small airways disease with air trapping appears to be a long-lasting sequela of SARS-CoV-2 infection, according to a prospective study that compared 100 COVID-19 survivors who had persistent symptoms and 106 healthy control participants.
"Something is going on in the distal airways related to either inflammation or fibrosis that is giving us a signal of air trapping," noted senior author Alejandro P. Comellas, MD, in a press release.[1] The study was stimulated by reports from University of Iowa clinicians noting that many patients with initial SARS-CoV-2 infection who were either hospitalized or were treated in the ambulatory setting later reported shortness of breath and other respiratory symptoms indicative of chronic lung disease.
Given the millions of COVID-19 infections worldwide, this finding may have a substantial potential impact on healthcare systems. While this initial study had limitations, emerging data continues to be a vital tool for earlier identification and initiation of appropriate treatment for active COVID-19 infections and PASC; thus, improving patient outcomes.
Investigators classified patients (mean age, 48 years; 66 women) with PASC according to whether they were ambulatory (67%), hospitalized (17%), or required treatment in the intensive care unit (ICU) (16%). They then compared computed tomography (CT) findings of patients who had COVID-19 and persistent symptoms with those of a healthy control group.
COVID-19 severity did not affect the percentage of cases of lung with air trapping among these patients. Air trapping occurred at rates of 25.4% among ambulatory patients, 34.6% in hospitalized patients, and in 27.3% of patients requiring intensive care (P = .1). The percentage of lung affected by air trapping in ambulatory participants was sharply and significantly higher than in healthy control participants (25.4% vs 7.2%; P < .001). Also, air trapping persisted; it was still present in 8 of 9 participants who underwent imaging more than 200 days postdiagnosis.
Qualitative analysis of chest CT images showed that the most common imaging abnormality was air trapping (58%); ground-glass opacities (GGOs) were found in 51% (46/91), noted Comellas and co-authors. This suggests ongoing lung inflammation, edema, or fibrosis. These symptoms are often observed during acute COVID-19, frequently in an organizing pneumonia pattern, and have been shown to persist for months after infection in survivors of severe disease. The mean percentage of total lung classified as having regional GGO on chest CT scans was 13.2% and 28.7%, respectively, in the hospitalized and ICU groups, both very much higher than in the ambulatory group, at 3.7% (P < .001 for both). Among healthy control participants, the GGO rate on chest CT was only 0.06% (P < .001).
In addition, air trapping correlated with the ratio of residual volume to total lung capacity (r = 0.6; P < .001) but not with spirometry results. In fact, the investigators did not observe airflow obstruction by spirometry in any group, suggesting that air trapping in these patients involves only small rather than large airways and that these small airways contribute little to total airway resistance. Only when a large percentage, perhaps 75% or more, of all small airways are obstructed will spirometry pick up small airways disease, the authors observed.
The findings taken together suggest that functional small airways disease (fSAD) and air trapping are consequences of SARS-CoV-2 infection, according to Comellas.
"If a portion of patients continues to have small airways disease, then we need to think about the mechanisms behind it," he said. "It could be something related to inflammation that's reversible, or it may be something related to a scar that is irreversible, and then we need to look at ways to prevent further progression of the disease."
He added, "Studies aimed at determining the natural history of [fSAD] in patients with post-acute sequelae of COVID-19 and the biological mechanisms that underlie these findings are urgently needed to identify therapeutic and preventative interventions," Comellas, professor of internal medicine at Carver College of Medicine, University of Iowa, Iowa City, concluded.
The study limitations, the authors stated, include the fact that theirs was a single-center study that enrolled participants infected early during the COVID-19 pandemic and did not include patients with delta or omicron variants, thus limiting the generalizability of the findings.
The study was published in Radiology.[2]
The reported findings "indicate a long-term impact on bronchiolar obstruction," stated Brett M. Elicker, MD, professor of clinical radiology, University of California, San Francisco, in an accompanying editorial.[3]
Because collagen may be absorbed for months after an acute insult, it is not entirely clear whether the abnormalities seen in the current study will be permanent.
Elicker said further, "the presence of [GGO] and/or fibrosis on CT were most common in the patients admitted to the ICU and likely correspond to post-organizing pneumonia and/or post-diffuse alveolar damage fibrosis."
He also pointed out that organizing pneumonia is especially common among patients with COVID-19 and is usually highly steroid-responsive. The opacities improve or resolve with treatment, but sometimes residual fibrosis occurs.
"Longer-term studies assessing the clinical and imaging manifestations 1-2 years after the initial infection are needed to fully ascertain the permanent manifestations of post-COVID fibrosis," Elicker concluded.
The study was supported by grants from the National Institutes of Health. The authors and Elicker have disclosed no relevant financial relationships.